Latest Price Spikes News

Wagners Holding Company Limited reported a robust FY25 with revenue growth led by construction materials and composite fibre technologies, alongside strategic expansion and debt reduction.

Wagners Holding Company Limited reported a solid FY25 with revenue of $431.3 million, driven by growth in construction materials and composite fibre technologies, while reducing net debt by 29%.

Kaili Resources has responded to an ASX price query following a dramatic rise in its share price, denying any undisclosed material information and confirming full compliance with ASX listing rules.

Vital Metals Limited has clarified the recent spike in its share price and trading volume, attributing it to a confidential capital raise and a positive scoping study amid a broader rare earths sector rally.

GTN Limited reported a modest revenue decline and a sharper EBITDA drop in FY25 but rewarded shareholders with strong returns including dividends, buybacks, and a significant capital return.

Xamble Group Limited has clarified that its recent share price surge is linked to a newly announced renounceable rights issue, dismissing speculation of undisclosed information.

DigitalX Limited has boosted its treasury valuation to A$104 million, driven by a strategic Bitcoin-first approach that now totals nearly 500 BTC. The company aims to more than quadruple its Bitcoin holdings by 2027, underscoring its confidence in digital assets as a core treasury component.

Resolute Mining Limited reported a robust half-year performance for H1 2025, with net profit more than doubling amid higher gold prices, even as production dipped due to operational challenges. The company also expanded its footprint with a strategic acquisition in Côte d’Ivoire.

Baby Bunting Group confirms its FY25 financial results align with prior guidance and analyst expectations, addressing ASX queries on disclosure timing amid notable share price movements.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Weebit Nano has responded to an ASX price query following a sharp rise in its share price and trading volume, attributing the activity to a misleading article on the Motley Fool website. The company denies any undisclosed price-sensitive information and confirms full compliance with ASX disclosure rules.

Ausmon Resources has addressed a recent spike in its share price and trading volume, attributing the market interest to prior drilling assay results for rare earth elements in South Australia.